Browse KIF2C

Summary
SymbolKIF2C
Namekinesin family member 2C
Aliases MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Nucleus Chromosome, centromere Chromosome, centromere, kinetochore Note=Associates with the microtubule network at the growing distal tip (the plus-end) of microtubules, probably through interaction with MTUS2/TIP150 and MAPRE1 (By similarity). Association with microtubule plus ends is also mediated by interaction with KIF18B. Centromeric localization requires the presence of BUB1 and SGO2.
Domain PF00225 Kinesin motor domain
Function

In complex with KIF18B, constitutes the major microtubule plus-end depolymerizing activity in mitotic cells (PubMed:21820309). Regulates the turnover of microtubules at the kinetochore and functions in chromosome segregation during mitosis (PubMed:19060894). Plays a role in chromosome congression and is required for the lateral to end-on conversion of the chromosome-microtubule attachment (PubMed:23891108).

> Gene Ontology
 
Biological Process GO:0000070 mitotic sister chromatid segregation
GO:0000226 microtubule cytoskeleton organization
GO:0000819 sister chromatid segregation
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0006890 retrograde vesicle-mediated transport, Golgi to ER
GO:0007018 microtubule-based movement
GO:0007019 microtubule depolymerization
GO:0007059 chromosome segregation
GO:0007062 sister chromatid cohesion
GO:0007067 mitotic nuclear division
GO:0007080 mitotic metaphase plate congression
GO:0007163 establishment or maintenance of cell polarity
GO:0008608 attachment of spindle microtubules to kinetochore
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
GO:0030951 establishment or maintenance of microtubule cytoskeleton polarity
GO:0030952 establishment or maintenance of cytoskeleton polarity
GO:0031109 microtubule polymerization or depolymerization
GO:0032984 macromolecular complex disassembly
GO:0043241 protein complex disassembly
GO:0043624 cellular protein complex disassembly
GO:0048002 antigen processing and presentation of peptide antigen
GO:0048193 Golgi vesicle transport
GO:0050000 chromosome localization
GO:0051261 protein depolymerization
GO:0051303 establishment of chromosome localization
GO:0051310 metaphase plate congression
GO:0051315 attachment of mitotic spindle microtubules to kinetochore
GO:0051640 organelle localization
GO:0051656 establishment of organelle localization
GO:0051983 regulation of chromosome segregation
GO:0098813 nuclear chromosome segregation
Molecular Function GO:0003774 motor activity
GO:0003777 microtubule motor activity
GO:0008017 microtubule binding
GO:0015631 tubulin binding
GO:0016887 ATPase activity
GO:0019237 centromeric DNA binding
GO:0051010 microtubule plus-end binding
Cellular Component GO:0000775 chromosome, centromeric region
GO:0000776 kinetochore
GO:0000777 condensed chromosome kinetochore
GO:0000779 condensed chromosome, centromeric region
GO:0000793 condensed chromosome
GO:0005871 kinesin complex
GO:0005874 microtubule
GO:0005875 microtubule associated complex
GO:0005881 cytoplasmic microtubule
GO:0035371 microtubule plus-end
GO:0098687 chromosomal region
GO:1990752 microtubule end
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-8856688: Golgi-to-ER retrograde transport
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-983189: Kinesins
R-HSA-68886: M Phase
R-HSA-2132295: MHC class II antigen presentation
R-HSA-199991: Membrane Trafficking
R-HSA-68882: Mitotic Anaphase
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-68877: Mitotic Prometaphase
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663220: RHO GTPases Activate Formins
R-HSA-2500257: Resolution of Sister Chromatid Cohesion
R-HSA-2467813: Separation of Sister Chromatids
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolKIF2C
Namekinesin family member 2C
Aliases MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KIF2C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between KIF2C and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24987109melanomaPromote immunity (infiltration)Both KIF2C and POLA2 have been found to play important roles in cell proliferation.
Summary
SymbolKIF2C
Namekinesin family member 2C
Aliases MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KIF2C in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKIF2C
Namekinesin family member 2C
Aliases MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KIF2C in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7120.0328
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7410.655
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6920.586
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5830.198
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3980.774
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8270.67
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0330.935
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.6280.65
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7250.606
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.010.99
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0690.952
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5090.000261
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KIF2C in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.46.80.61
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKIF2C
Namekinesin family member 2C
Aliases MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KIF2C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKIF2C
Namekinesin family member 2C
Aliases MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KIF2C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KIF2C.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKIF2C
Namekinesin family member 2C
Aliases MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KIF2C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKIF2C
Namekinesin family member 2C
Aliases MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KIF2C expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKIF2C
Namekinesin family member 2C
Aliases MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KIF2C and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKIF2C
Namekinesin family member 2C
Aliases MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KIF2C collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting KIF2C.
ID Name Drug Type Targets #Targets
DB04395Phosphoaminophosphonic Acid-Adenylate EsterSmall MoleculeACTA1, CCT3, CFTR, CSNK2A1, DAPK1, DTYMK, EPHA2, EPHB2, GALK1, GSK ......26